NewsBenzingaアキュメン・ファーマ、アルツハイマー病試験でALTITUDE-ADの主要評価項目と主要な副次評価項目を達成できずと発表;同社はサビルネツグの臨床開発を中止し、現金を温存して戦略的選択肢を検討へ アキュメン・ファーマ、アルツハイマー病試験でALTITUDE-ADの主要評価項目と主要な副次評価項目を達成できずと発表;同社はサビルネツグの臨床開発を中止し、現金を温存して戦略的選択肢を検討へ Benzinga 2026.10.30 11:13 (GMT+0) Open on Benzinga Other news Arthur Hayes: Bullish on ETH, ZEC, NEAR and VVV, Has Built Small- and Mid-Sized Positions Huang's Nvidia Return Odds Rebound to 11% on Kalshi Hackers Spread Crypto-Stealing Trojan via Fake GTA 6 PC Download Links Invesco's Stablecoin Reserve Fund Goes Live on Ethereum 7 Major US Banks Disclose XRP ETF Holdings in SEC Filings, Totaling About $29.4M Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading
Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading